A Phase 1 Multi-center Open-label Dose De-escalation Study to Evaluate the Safety and Efficacy of Talimogene Laherparepvec in Pediatric Subjects with Advanced Non-Central Nervous System Tumors That are Amenable to Direct Injection
This is a phase 1 study to evaluate the safety of intralesional talimogene laherparepvec administration in pediatric subjects with advanced non-CNS tumors that are amenable to direct injection.
This is a phase 1, multicenter, open-label study of talimogene laherparepvec in pediatric subjects with advanced non-CNS tumors that are amenable to direct injection in the clinical setting.
- IRB Number: 1601440687 (PHO-CROOP-AMGEN-20110261)
- Research Study Identifier: TX6202
- Principal Investigator: James Croop, MD, PhD
Contact the research team to learn more about this study.
Fields marked with asterisk (*) are required